We're delighted to partner with 2 other leading Irish cancer charities: BreastCancerIreland Marie Keating Foundation to launch faceuptocancer.ie This is a fundraising campaign asking people to donate & upload their selfies in support of cancer research & cancer support services. Join us!

DreaMM-7: Bela-Vd vs Dara-Vd mPFS 36.6 vs 13.4 months Only 33% Len refractory Very few Dara-exposed 34% grade 3 ocular AEs 19% vs 9% discontinuation rate Would ocular AEs be mitigated by different dosing? Could bela-Vd be a good option for post Dara-Rd relapse?

Excellent work by Stephanie on BH3 profiling in myeloma RCSI

Huge congratulations🎉 to Lyndsey Flanagan, her PhD research on enhancing venetoclax response in #MultipleMeyloma was published in @haemtologica in collaboration with Siobhan Glavey Beaumont RCSI Cancer Centre Thanks to funders Breakthrough Cancer Research Leukemia Research Foundation 📔:haematologica.org/article/view/h…

Thrilled to see research, funded by Breakthrough Cancer Research offering new avenues of treatment options for Multiple Myeloma. Congratulations to Dr. Lyndsey Flanagan, Prof. Triona Ní Chonghaile, Prof. Siobhan Glavey all at RCSI & Beaumont RCSI Cancer Centre on this exciting discovery independent.ie/irish-news/new…

Join me tomorrow with Irish Cancer Society for our webinar on Multiple Myeloma in Ireland 🇮🇪

Take on the ROK Charity Cycle 2024🚴‍♂️ Join us on this 170km cycle along one of Ireland’s most breathtaking landscapes while helping to raise much needed funds for cancer research🔬Sign up here👉 ringofkerrycycle.ie/our-charities/… #RingOfKerryCharityCycle #ROKCC #CharityCycle #CancerResearch

CRISPR editing is hard. Editing in primary human cells is even harder. Editing non-coding variants in human cells is downright impossible. I am happy to share our work aimed at addressing this problem with Soumya Raychaudhuri সৌম্য রায়চৌধুরী Broad Institute Mass General Brigham biorxiv.org/content/10.110…

New IMS high risk definition for multiple myeloma presented by Prof Corre COMy . Fantastic effort by co-operative groups to redefine risk. Clearly an evolving area.

Of course this wouldn’t have been possible without the amazing support of my supervisors Triona Ní Chonghaile Siobhan Glavey incredibly lucky to have worked with two fantastic scientists! A huge thank you to Breakthrough Cancer Research Physiology RCSI

BENEFIT/IFM2020-05 Study. X Leleu. N=270 1;1 rand. ! endpoint MRD 10-6. Weekly bortezomib #mmsm #ASCO24RF

The June Issue of Kidney News is now available online! This issue highlights topics such as caregiver support in nephrology, the use of SGLT2 inhibitors to prevent kidney stones, and a special section focused on nutrition and kidney health, and more bit.ly/3yMtgnU

Very proud of Niamh McAuley presenting her work on JAM-A and 1q MM at EHA today, more to come from this work on high-risk MM #EHA2024 Breakthrough Cancer Research #mmsm

Check out poster 880 European Hematology Association #EHA2024 now in poster session, evaluating EMD spatial heterogeneity in Irish MM patients, and Sahin is pretty fun too 👉shown here on the left 👏#mmsm

#Myeloma Paper of the Day: Comparison of International Myeloma Working Group frailty index (IMWG‐FI) & Simplified Frailty Index (Simplified‐FI) suggests the latter identifies more patients as frail vs. former & could lead to under-treatment of some: pubmed.ncbi.nlm.nih.gov/38966208/. #mmsm

I just heard about a myeloma patient who is 21 years post-ASCT with no additional maintenance or relapse. Way on the right side of the bell curve. If eligible, I guess don't throw ASCT out the window yet! #mmsm

MRD is here - RCSI post doc Róisín McAvera takes us through the when and how for myeloma patients Beaumont RCSI Cancer Centre #myelomainireland

Minimal Residual Disease (MRD) is the number of myeloma cells left after treatment. Your doctor may perform the same tests from your initial diagnosis to see how well treatment is working. Download our Treatment Overview booklet: ow.ly/RRzC50Tne93 #BloodCancerAwarenessMonth